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Abstract
This study aimed to investigate the prevalence and clinical significance of lead-related tri-
cuspid regurgitation (TR) in patients with permanent pacemaker (PM). A total of 2,533
patients who underwent permanent PM implantation between January 2008 and December
2017 in a single center were retrospectively reviewed. Among them, 429 patients who
underwent transthoracic echocardiography within 90 days before implantation and were fol-
lowed up at least 3 months after PM implantation were included. Patients who had pre-exist-
ing grade 3 or 4 TR, had a single atrial lead, or had undergone tricuspid valve surgery before
PM implantation were excluded. Occurrence of PM-related TR (PMTR) was defined as
worsening of TR by at least 2 grades on follow-up echocardiography. Cardiovascular out-
comes were defined as the composite of cardiovascular death and hospitalization for heart
failure. During the median follow-up of 855 days, 42 (9.8%) patients had PMTR and 86
(20.0%) presented with cardiovascular outcomes. In the multivariate logistic regression
analysis, the presence of atrial fibrillation (hazard ratio [HR]: 2.07, 95% confidence interval
[CI]: 1.27–4.09, p = 0.037]) and history of open-heart surgery (HR: 3.34, 95% CI: 1.68–6.68,
p<0.001) were independently associated with PMTR. Patients with PMTR showed signifi-
cantly higher cardiovascular events than those without (45.2 vs. 17.3%, log-rank p<0.001).
Furthermore, PMTR was independently associated with the primary outcome (HR: 2.45,
95% CI: 1.43–4.22, p = 0.001). In conclusion, the occurrence of TR in patients with perma-
nent PM is not uncommon. PMTR is associated with atrial fibrillation, the history of open-
heart surgery, and poorer cardiovascular outcomes.
Introduction
Implantation of permanent pacemakers (PM) has gradually increased because of either pro-
longed life expectancy or increased incidence of cardiac surgery [1, 2]. Tricuspid regurgitation
(TR) is recognized as one of the lead-related complications [1, 3, 4]. PM-related TR (PMTR)
can occur due to direct leaflet damage, such as leaflet perforation, lead entanglement, or lead
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adherence from fibrosis [2, 5]. In addition, TR can be aggravated through annular dilatation
and chronic right ventricular (RV) dysfunction regardless of the mechanical interference to
the valve by the electrode [6].
Several previous studies have demonstrated that moderate or severe TR occurred at a signif-
icant higher rate in patients with PM and was associated with higher mortality and heart fail-
ure-related hospitalization than that in risk-matched cohorts [7–9]. Although clinical
implications of PMTR are largely concordant among previous studies[7–9], diverse predictors
of PMTR have been proposed in each study. Alternative strategies to pace the heart without
passing through the tricuspid valve, such as the placement of a coronary sinus pacing lead, sur-
gical epicardial placement of leads, and leadless pacing systems, are currently available [10,
11]. Furthermore, echocardiography guidance at the time of PM implantation might be helpful
to avoid acute leaflet damage by a transvenous lead in high-risk patients for PMTR. Therefore,
we sought to investigate the prevalence, predictors, and prognosis of PMTR in a large, single-
center registry involving a wide spectrum of patients who underwent permanent PM implan-
tation in this study.
Materials and methods
Study population
A total of 2,533 patients who underwent de novo permanent PM implantation at a single
tertiary center between January 2008 and December 2017 were included in this analysis.
Among them, 429 patients who underwent transthoracic echocardiography within 90 days
before implantation and underwent follow-up at least 3 months after PM implantation were
included. Data on baseline patient characteristics, implantation procedure, device charac-
teristics and setting, and all follow-up visits were retrospectively reviewed. Indications for
device implantation, based on international guidelines, were sick sinus syndrome and
advanced atrioventricular block in PM recipients. We excluded patients who had grade 3 or
4 TR before PM implantation; were treated with a single-lead atrial PM, implantable cardio-
verter defibrillator, or cardiac resynchronization therapy; had a history of tricuspid valve
repair; had an inadequate quality of echocardiographic data for assessment of RV function
and degree of TR; or had undergone a temporary PM implantation (Fig 1). PMTR was
defined as TR worsened by at least 2 grades on post-implantation echocardiography during
the follow-up period. Patients were divided into two groups according to the occurrence of
PMTR: Group 1 (n = 387, no PMTR) and Group 2 (n = 42, PMTR). The study was approved
by the Institutional Review Board of Yonsei University Health System (approval number: 4-
2020-0032), and it complied with the Declaration of Helsinki. As registry-based retrospec-
tive study and the data were analyzed anonymously, it did not require informed consent
from the study subjects.
Echocardiography
Standard two-dimensional and Doppler measurements were performed following the Ameri-
can Society of Echocardiography guidelines [12]. TR severity was graded semi-quantitatively
using colored and continuous wave Doppler data using a multi-parametric approach [13, 14].
RV systolic dysfunction was evaluated by two-dimensional echocardiography. RV area mea-
surements were obtained from the apical four-chamber focused RV view at end-diastole and
end-systole, and RV fractional area change was calculated as the ratio between the difference
at the end-diastolic and end-systolic RV areas and the end-diastolic area [12]. The TV annulus
dimension (TVAD) was measured as the end-diastole in the apical four-chamber view and
then indexed by the body surface area (BSA) [13]. The RV systolic pressure was calculated
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from the maximum velocity of the TR jet according to the modified Bernoulli equation [12].
Echocardiographic data were carefully reviewed by two experienced cardiologists who were
blinded to the clinical data.
Follow-up and outcomes
Patients were regularly scheduled to visit the PM clinic every 6 months after PM implantation.
Follow-up data were obtained by reviewing medical records. If patients did not visit on the
scheduled day, outcome data were assessed via telephone interview. The primary outcome was
defined as a composite of cardiovascular death and hospitalization due to heart failure during
the follow-up period.
Statistical analysis
Continuous variables were expressed as mean ± standard deviation. Categorical variables were
expressed as number (percentage). Between-group comparisons were performed using stan-
dard χ2 tests for categorical variables and paired t-tests for continuous variables. Univariate
and multivariate logistic regression analyses were performed. Comparison of worsening of TR,
mitral regurgitation (MR) and RV systolic pressure (RVSP) in tertile of ventricular pacing per-
centage were performed using the standard χ2 tests and analysis of variance (ANOVA) test.
Pearson’s correlation coefficient was used to test the linear relation between the percentage of
ventricular pacing and RVSP. Survival curves were constructed using the Kaplan–Meier
method, and comparisons were made using the log-rank test. All statistical analyses were per-
formed using SPSS Statistics software version 25.0 (IBM, Armonk, NY, USA); p-values < 0.05
were considered statistically significant.
Fig 1. Flowchart of the study.
https://doi.org/10.1371/journal.pone.0235230.g001
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Results
Baseline characteristics
Among 429 patients, 42 (9.8%) had PMTR. Clinical and echocardiographic characteristics of
the study population, patients without PMTR, and those with PMTR are summarized in
Table 1. Patients with PMTR tended to be older and of the female sex (without statistical sig-
nificance). Patients with PMTR had a significantly higher incidence of previous open-heart
surgery than those without PMTR. Regarding PM data, patients with PMTR showed a higher
Table 1. Baseline characteristics.
Total (n = 429) No PMTR (n = 387) PMTR (n = 42) P-value
Demographic data
Age, years 67.0 ± 12.8 66.7 ± 13.0 70.3 ± 10.4 0.078
Male sex, n (%) 176 (41.0) 164 (42.4) 12 (28.6) 0.118
Body mass index, kg/m2 24.2 ± 3.5 24.2 ± 3.5 23.9 ± 3.5 0.580
Hypertension, n (%) 256 (59.7) 226 (58.4) 30 (71.4) 0.142
Diabetes mellitus, n (%) 104 (24.2) 91 (23.5) 13 (31.0) 0.380
Atrial fibrillation, n (%) 131 (30.5) 114 (29.5) 17 (40.5) 0.195
CAD, n (%) 53 (12.4) 47 (12.1) 6 (14.3) 0.878
Open-heart surgery, n (%) 71 (16.6) 57 (14.7) 14 (33.3) 0.004
MV surgery 21 (4.9) 16 (4.1) 5 (11.9) 0.066
AV surgery 43 (10.0) 35 (9.0) 8 (19.0) 0.075
CABG 8 (1.9) 6 (1.6) 2 (4.8) 0.389
Others 11 (2.6) 10 (2.6) 1 (2.4) >.999
Pacemaker data
V pacing percentage, % 61.1 ± 42.5 61.5 ± 42.8 57.5 ± 40.3 0.571
Indication
AV node disease, n (%) 264 (61.5) 238 (61.5) 26 (61.9) >.999
Sinus node disease, n (%) 165 (38.5) 149 (38.5) 16 (38.1) >.999
Mode
DDD, n (%) 348 (81.1) 322 (83.2) 26 (61.9) 0.002
VDD, n (%) 7 (1.6) 7 (1.8) 0 (0.0) 0.812
VVI, n (%) 25 (5.8) 17 (4.4) 8 (19.0) < .001
Echocardiographic data
LVEF, % 65.6 ± 9.6 65.7 ± 9.5 65.2 ± 10.2 0.770
LA volume index, ml/m2 43.3 ± 17.8 43.3 ± 17.6 43.7 ± 19.9 0.902
RVEDA, cm 18.8 ± 7.3 19.0 ± 7.6 17.0 ± 4.2 0.008
RVESA, cm 10.2 ± 3.7 10.3 ± 3.8 9.3 ± 2.8 0.048
RVFAC, % 45.8 ± 9.0 45.8 ± 9.1 45.0 ± 8.9 0.568
TVAD, mm 29.5 ± 4.6 29.5 ± 4.6 29.5 ± 4.0 0.951
TVAD/BSA, mm/m2 18.1 ± 3.1 18.0 ± 3.1 18.3 ± 2.9 0.531
RVSP, mmHg 33.2 ± 12.6 33.4 ± 13.0 31.5 ± 9.1 0.224
Tricuspid regurgitation 0.398
No, n (%) 287 (66.9) 255 (65.9) 32 (76.2)
Grade 1, n (%) 110 (25.6) 102 (26.4) 8 (19.0)
Grade 2, n (%) 32 (7.5) 30 (7.8) 2 (4.8)
PMTR, pacemaker-related tricuspid regurgitation; CAD, coronary artery disease; MV, mitral valve; AV, aortic valve; CABG, coronary artery bypass graft; AVB,
Atrioventricular block; LVEF, left ventricular ejection fraction; LA, left atrium; RVEDA, right ventricular end-diastole area; RVESA, right ventricular end-systole area;
TVAD, tricuspid valve annular diameter; BSA, body surface area; RVSP, right ventricular systolic pressure.
https://doi.org/10.1371/journal.pone.0235230.t001
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incidence of VVI mode although the V pacing percentage and indications for PM implanta-
tion were comparable. In terms of echocardiographic characteristics, patients with PMTR
showed smaller RV end-diastole area and RV end-systole area than those without PMTR,
although other echocardiographic variables were comparable, including left heart size and
function, TVAD, RV systolic pressure, and initial TR grades. The smaller RV area in patients
with PMTR seems to be associated with fewer cases of grade 1 or 2 TR in that group than in
the group without PMTR, owing to the criteria for dividing the two groups.
Predictors for PMTR
Table 2 shows the factors associated with the development of PMTR. In the multivariate logis-
tic regression analysis, the presence of atrial fibrillation (hazard ratio [HR] 2.07, 95% confi-
dence interval [CI] 1.27–4.09, p = 0.037) and history of open-heart surgery (HR 3.34. 95% CI
1.68–6.68, p < 0.001) were independently associated with PMTR. Among echocardiographic
variables, TVAD/BSA tended to be associated with PMTR, but the statistical significance was
marginal (HR 1.12, 95% CI 0.99–1.26, p = 0.054). The presence of grade 1 or 2 TR on pre-
implantation echocardiography did not increase the risk of PMTR compared to the absence of
TR. The results of subgroup analysis of multivariate Cox proportional hazard ratios for PMTR
according to the history of open-heart surgery are shown in Table 3. Comparison of worsening
of TR, MR and RVSP in tertile of ventricular pacing percentage were presented in Table 4.
There were no significant relationships between increase of ventricular pacing percentage and
worsening of TR or MR. On the contrary, RVSP was correlated with percentage of ventricular
pacing in Pearson’s correlation coefficient (R = 0.154, p = 0.001).
Impact of PMTR on clinical outcomes
During the median follow-up of 855 days, patients with PMTR showed significantly higher
cardiovascular events than those without (45.2% vs. 17.3%, log-rank p<0.001) (Fig 2A). PMTR
Table 2. Multivariate Cox proportional hazard ratios for pacemaker-related tricuspid regurgitation.
HR (95% CI) P-value
Age 1.03 (0.99–1.06) 0.072
Male sex 0.67 (0.32–1.37) 0.271
Atrial fibrillation 2.07 (1.27–4.09) 0.037
Open-heart surgery 3.34 (1.68–6.68) <0.001
V pacing percentage 1.00 (0.99–1.01) 0.901
LVEF 1.01 (0.97–1.04) 0.789
LA volume index 1.00 (0.98–1.02) 0.893
RVEDA 0.93 (0.86–1.02) 0.114
RVFAC 0.99 (0.95–1.02) 0.444
TVAD/BSA 1.12 (0.99–1.26) 0.054
RVSP 1.00 (0.97–1.03) 0.893
Tricuspid regurgitation
No Ref Ref
Grade 1 0.47 (0.20–1.11) 0.086
Grade 2 0.43 (0.08–2.24) 0.314
HR, hazard ratio; CI, confidence interval; LVEF, left ventricular ejection fraction; LA, left atrium; RVEDA, right
ventricular end-diastole area; RVESA, right ventricular end-systole area; TVAD, tricuspid valve annular diameter;
BSA, body surface area; RVSP, right ventricular systolic pressure.
https://doi.org/10.1371/journal.pone.0235230.t002
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was independently associated with primary outcomes (HR: 2.45, 95% CI: 1.43–4.22, p = 0.001)
even after controlling for age; sex; comorbidities including coronary artery disease, atrial fibril-
lation, and history of open-heart surgery; and echocardiographic variables including LV ejec-
tion fraction and LA volume index (Table 5). In the subgroup analysis according to the history
of open-heart surgery, the clinical impact of PMTR was consistent in patients without a history
of open-heart surgery (Fig 2B, log-rank p = 0.002, HR 2.44, 95% CI 1.28–4.62, p = 0.007,
Table 6) and in those with a history of open-heart surgery (Fig 2C, log-rank p = 0.014, HR
1.43, 95% CI 1.48–4.33, p = 0.012, Table 6).
Discussion
The primary findings of this study were as follows: 1) the prevalence of PMTR was 9.7% in this
study population during a median follow-up of 855 days; therefore, it was not uncommon; 2)
the occurrence of PMTR was associated with atrial fibrillation and a history of open-heart sur-
gery; and 3) PMTR was associated with poorer cardiovascular outcome. Therefore, we would
suggest that echocardiographic surveillance of PMTR should be performed in patients who
underwent PM implantation, especially in those with atrial fibrillation or a history of open-
heart surgery.
Table 3. Subgroup analysis of multivariate Cox proportional hazard ratios for PMTR according to the history of
open-heart surgery.
No open-heart surgery (n = 358) Open-heart surgery (n = 71)
HR (95% CI) P value HR (95% CI) P value
Age 1.03 (0.98–1.05) 0.395 1.07 (0.98–1.05) 0.045
Male sex 0.84 (0.34–2.07) 0.698 0.61 (0.34–2.07) 0.529
Atrial fibrillation 1.91 (0.79–4.62) 0.151 3.24 (0.87–12.06) 0.080
V pacing percentage 1.00 (0.99–1.01) 0.885 1.00 (0.98–1.02) 0.948
LVEF 0.99 (0.95–1.04) 0.827 1.03 (0.95–1.04) 0.349
LA volume index 0.99 (0.96–1.01) 0.313 0.99 (0.96–1.01) 0.617
RVEDA 0.92 (0.83–1.02) 0.101 1.02 (0.84–1.24) 0.832
RVFAC 0.99 (0.95–1.04) 0.717 1.01 (0.94–1.09) 0.840
TVAD/BSA 1.12 (0.96–1.30) 0.158 1.28 (0.98–1.65) 0.065
RVSP 1.01 (0.97–1.06) 0.554 1.02 (0.95–1.10) 0.557
TR
No Ref Ref Ref
Grade 1 0.16 (0.03–0.77) 0.022 1.60 (0.33–7.71) 0.559
Grade 2 0.01 (0.08-inf) 0.997 1.54 (0.16–15.12) 0.712
HR, hazard ratio; CI, confidence interval; LVEF, left ventricular ejection fraction; LA, left atrium; RVEDA, right
ventricular end-diastole area; RVESA, right ventricular end-systole area; TVAD, tricuspid valve annular diameter;
BSA, body surface area’ RVSP, right ventricular systolic pressure.
https://doi.org/10.1371/journal.pone.0235230.t003
Table 4. Comparison of worsening of TR, MR and RVSP in tertile of ventricular pacing percentage.
V pacing <30% (n = 147) V pacing 30 to 99.5% (n = 133) V pacing >99.5% (n = 149) P-value
PMTR, n (%) 14 (9.5) 17 (12.8) 11 (7.4) 0.311
Worsening of MR, n (%) 23 (15.6) 24 (18.0) 17 (11.4) 0.282
RV systolic pressure, mmHg ± SD 30.7 ± 9.8 34.8 ± 14.1 34.4 ± 13.4 0.011
V pacing, Ventricular pacing percentage; PMTR, pacemaker-related tricuspid regurgitation; MR, mitral regurgitation; RV, right ventricle.
https://doi.org/10.1371/journal.pone.0235230.t004
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The results of this study are generally concordant with those of previous studies on the poor
prognostic impact of PMTR [7–9]. However, the study population of each study is notably dif-
ferent. Höke et al. demonstrated that significant lead-induced TR is associated with poor long-
term prognosis in 287 patients who underwent Implantable cardioverter defibrillator (ICD) or
pacemaker implantation. They included 191 patients with ICD and excluded patients who
underwent cardiac valve surgery. Therefore, the baseline LV ejection fraction of the study was
39 ± 14% because of a large proportion of patients with ICD implantation for primary or sec-
ondary prevention [9]. In contrast, the baseline LV ejection fraction in this study was
66 ± 10%, as we excluded patients who underwent ICD implantation or cardiac resynchroniza-
tion therapy. Moreover, 16.6% of patients had a history of open-heart surgery, and of these,
the majority were cardiac valve surgeries in the mitral or aortic position. Delling et al. also
revealed that permanent PM-related significant TR was not a benign phenomenon but was
associated with an increased mortality risk compared to that in patients with permanent PM
without significant TR [9]. The study did not exclude patients with pre-existing grade 3 or 4
TR before PM implantation, and information regarding the presence of atrial fibrillation at
baseline was lacking. Another study by Al-Bawardy et al. also did not exclude patients with
pre-existing grade 3 or 4 TR from their study, and 62% of their study population had ICDs [7].
Therefore, this study provides further information regarding the prevalence, predictors, and
Fig 2. Kaplan–Meier curves for the primary outcome-free survival according to the presence of pacemaker-related tricuspid regurgitation A. overall patients, B. patients
without previous open-heart surgery, and C. patients with previous open-heart surgery.
https://doi.org/10.1371/journal.pone.0235230.g002
Table 5. Multivariate Cox proportional hazard ratios for primary outcomes.
HR (95% CI) P-value
Age 1.05 (1.03–1.08) <0.001
Male sex 1.19 (0.77–1.85) 0.437
CAD 1.14 (0.64–2.05) 0.656
Atrial fibrillation 1.23 (0.78–1.96) 0.377
Open-heart surgery 0.86 (0.48–1.53) 0.602
LVEF 0.96 (0.94–0.98) <0.001
LA volume index 1.00 (0.99–1.01) 0.707
PMTR 2.45 (1.43–4.22) 0.001
CAD, coronary artery disease; LVEF, left ventricular ejection fraction; LA, left atrium; PMTR, pacemaker-related
tricuspid regurgitation.
https://doi.org/10.1371/journal.pone.0235230.t005
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prognosis of PMTR by including only patients with permanent PM in a wide spectrum of
underlying disease including patients with history of open-heart surgery.
The etiology and mechanism of PMTR are not fully elucidated. Earlier studies mainly
showed direct damage to TV leaflet or subvalvular apparatus during pacemaker lead implanta-
tion can lead to PMTR by perforation of TV leaflet, laceration, or injury of chordae tendineae
[15–17]. However, more recent studies have demonstrated that mechanical interference of TV
leaflet or subvalvular structures which resulted in incomplete coaptation of TV [3, 5]. Another
mechanism of lead-related PMTR is fibrotic response and adhesion of lead and TV leaflet.
One study reported that lead adherence to the TV leaflet occurred in 14 out of 41 patients with
severe TR due to a permanent pacemaker or ICD [2]. Pacing-related TR also one of the possi-
ble mechanism of PMTR. Since LV dyssynchrony and left bundle branch block is an estab-
lished cause of mitral regurgitation [18], RV dyssynchrony due to permanent pacing is
considered can lead to a worsening of TR [6]. In this study, atrial fibrillation and a history of
open-heart surgery were found to be independent predictors of PMTR. This finding suggested
that the mechanism of PMTR in this population is likely to involve secondary TR, including
interference of TV leaflet coaptation, lead adherence, or pacing-related TR rather than primary
TR related with direct leaflet damage by the PM lead. Moreover, the larger TVAD/BSA on
baseline echocardiogram before PM implantation tends to be associated with PMTR after
adjusting for the RV area and presence of atrial fibrillation, which also supports the suggested
mechanism.
With the increase in the aging population and recent advances in surgical and transcatheter
intervention, many patients who underwent permanent PM implantation had atrial fibrillation
and a history of valve procedure. Conduction abnormality requiring permanent PM implanta-
tion are frequent and associated with an increased risk of heart failure-related hospitalization
and lack of functional improvement and reverse remodeling after either transcatheter or surgi-
cal aortic valve implantation [19–21]. Data regarding the prognostic impact of PM implanta-
tion after valve intervention are somewhat controversial. A few studies demonstrated no
prognostic impact of PM implantation after valve implantation [19, 22]; however, some studies
showed worse outcome in patients who received permanent PM implantation [21, 23]. These
discrepancies may possibly be related to the involvement of the occurrence of PMTR between
the PM implantation and clinical outcome. In this study, the clinical implication of PMTR was
also significant in the subgroup of patients with a history of open-heart surgery.
This study has several limitations. First, this study was retrospectively designed, resulting in
an inherent potential limitation. Patients who did not undergo follow-up echocardiography
Table 6. Subgroup analysis of the multivariate Cox proportional hazard ratios for primary outcomes according to
the history of open-heart surgery.
No open-heart surgery (n = 358) Open-heart surgery (n = 71)
HR (95% CI) P value HR (95% CI) P value
Age 1.06 (1.03–1.09) < .001 1.07 (1.03–1.11) 0.623
Male sex 1.39 (0.84–2.28) 0.199 2.85 (1.25–6.50) 0.614
CAD 1.10 (0.57–2.15) 0.770 0.47 (0.13–1.65) 0.717
Atrial fibrillation 1.52 (0.92–2.50) 0.101 1.28 (0.56–2.96) 0.258
LVEF 0.97 (0.94–0.99) 0.005 0.96 (0.93–0.99) 0.028
LA volume index 1.01 (0.99–1.02) 0.155 1.00 (0.97–1.02) 0.433
PMTR 2.44 (1.28–4.62) 0.007 1.43 (1.48–4.33) 0.012
CAD, coronary artery disease; LVEF, left ventricular ejection fraction; LA, left atrium; PMTR, pacemaker-related
tricuspid regurgitation.
https://doi.org/10.1371/journal.pone.0235230.t006
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were excluded, and the interval after PM implantation in each patient was not preset in real
clinical practice. Therefore, the prevalence of PMTR may possibly be underestimated. Second,
a few studies have demonstrated that three-dimensional echocardiography might be better for
the assessment of lead-TV interaction [24, 25], but we did not perform an analysis using three-
dimensional echocardiography findings. Therefore, the mechanism of PMTR could not be
determined in detail. Third, although one of the possible mechanism of pacing related TR is
RV dyssynchrony, we did not include RV dyssynchrony analysis due to unavailable echocar-
diographic data for the analysis. However, we assumed that the main findings of the study are
not substantially affected by RV dyssynchrony because percentage of ventricular pacing was
not significantly associated with increasing of TR.
In conclusion, worsening of TR is not uncommon in patients with permanent PM and is
associated with the presence of atrial fibrillation and a history of open-heart surgery. PMTR is
independently associated with poor cardiovascular outcome. Thus, baseline and regular fol-
low-up echocardiographic surveillance should be performed after PM implantation, especially
in patients with atrial fibrillation and a history of open-heart surgery.
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